Trade

with

Insys Therapeutics Inc
(NASDAQ: INSY)
AdChoices
38.81
-0.22
-0.56%
After Hours :
38.81
0.00
0.00%

Open

39.44

Previous Close

39.03

Volume (Avg)

392.16k (537.93k)

Day's Range

38.25-40.44

52Wk Range

20.52-57.91

Market Cap.

1.34B

Dividend Rate ( Yield )

-

Beta

1.31

Shares Outstanding

34.51M

P/E Ratio (EPS)

26.95 (1.44)

AdChoices
Fundamentals
  • Key statistics
  • Growth
  • Profitability
  • Financial health
  • Price ratios
  • Trading statistics
Industry Biotechnology
Highlights
Analyst Recommendation: Buy
    • Revenue

    • 99.29M

    • Net Income

    • 40.38M

    • Market Cap.

    • 1.34B

    • Enterprise Value

    • -

    • Net Profit Margin %

    • 31.67

    • PEG (Price/Earnings Growth) Ratio

    • 0.61

    • Beta

    • 1.31

    • Forward P/E

    • 17.79

    • Price/Sales

    • 8.55

    • Price/Book Value

    • 11.03

    • Price/Cash flow

    • 32.36

      • EBITDA

      • 34.29M

      • Return on Capital %

      • 53.17

      • Return on Equity %

      • 67.83

      • Return on Assets %

      • 53.17

      • Book Value/Share

      • 3.52

      • Shares Outstanding

      • 34.51M

      • Last Split Factor (Date)

      • -

      • Last Dividend (Ex-Date)

      • -

      • Dividend Declaration Date

      • -

      Analyst Recommendation
      10/20/2014
      Buy
        • 1 Year Price Target

        • 40.00

        • Credit Rating

        • -

        • Analysts

        • 2

        • EPS Estimate

        • 1.80

        • Cashflow Estimate

        • 2.56

        Morningstar Consensus estimate data
        • Growth Rate (%)

        • Company

        • Industry

          • Sales (Revenue)

            Q/Q (last year)

          • 195.90

          • 40.73

          • Net Income

            YTD/YTD (last year)

          • -

          • 17.04

          • Net Income

            Q/Q (last year)

          • 108.20

          • 98.90

          • Sales (Revenue)

            5-Year Annual Average

          • 104.69

          • 63.43

          • Net Income

            5-Year Annual Average

          • -

          • 10.65

          • Dividends

            5-Year Annual Average

          • -

          • 15.81

          • Profit Margins (%)

          • Company

          • Industry

            • Gross Margin

            • 88.22

            • 82.75

            • Pre-Tax Margin

            • 32.63

            • 39.38

            • Net Profit Margin

            • 31.67

            • 31.33

            • Average Gross Margin

              5-Year Annual Average

            • -

            • 82.99

            • Average Pre-Tax Margin

              5-Year Annual Average

            • -

            • 33.42

            • Average Net Profit Margin

              5-Year Annual Average

            • -

            • 199.05B

            • Financial Ratios

            • Company

            • Industry

              • Debt/Equity Ratio

              • -

              • 0.76

              • Current Ratio

              • 3.61

              • 2.92

              • Quick Ratio

              • 2.49

              • 2.35

              • Interest Coverage

              • -3,199.71

              • 38.02

              • Leverage Ratio

              • 1.23

              • 2.21

              • Book Value/Share

              • 3.52

              • 4.76

              • Price Ratios

              • Company

              • Industry

                • Current P/E Ratio

                • 25.97

                • 196.08

                • P/E Ratio 5-Year High

                • 40.27

                • 634.30

                • P/E Ratio 5-Year Low

                • 0.49

                • 124.82

                • Price/Sales Ratio

                • 8.22

                • 9.12

                • Price/Book Value

                • 10.60

                • 8.26

                • Price/Cash Flow Ratio

                • 32.36

                • 47.39

                • Key Metrics

                • Company

                • Industry

                  • Return on Equity %

                    (5-Year Average)

                  • 67.83

                    (-)

                  • 37.63

                    (27.20)

                  • Return on Assets %

                    (5-Year Average)

                  • 53.17

                    (-)

                  • 17.22

                    (13.81)

                  • Return on Capital %

                    (5-Year Average)

                  • 67.81

                    (-)

                  • 21.78

                    (17.31)

                  • Income/Employee

                  • 261.44k

                  • 117.08k

                  • Inventory Turnover

                  • 1.18

                  • 1.48

                  • Asset Turnover

                  • 1.68

                  • 0.55

                  Current Historical
                  Financials
                  • Income Statement
                  • Balance Sheet
                  • Cash Flow
                  Operating Income
                  32.56M
                  Operating Margin
                  32.79
                  Total Equity
                  -
                  Retained Earnings
                  -
                  Free Cashflow
                  -
                  Price/Cashflow
                  32.36
                  Ownership

                  Institutional Ownership

                  -

                  Top 10 Institutions

                  114.94%

                  Mutual Fund Ownership

                  15.99%

                  Float

                  -

                  5% / Insider Ownership

                  0.86%

                  Corporate insiders or major stockholders reporting trading activity in the stock.

                  Top Mutual Fund Owners

                  Top Institutional Owners

                  Mutual Fund Name

                  Institution Name

                  • Mutual Fund Name

                  • Shares Held

                  • % Change

                  • % Outstanding

                  • Fidelity® Select Biotechnology Portfolio

                  •  

                    869,478

                  • 0.00

                  • 2.52

                  • Janus Global Life Sciences Fund

                  •  

                    637,922

                  • 76.49

                  • 1.85

                  • iShares Nasdaq Biotechnology

                  •  

                    457,582

                  • -0.69

                  • 1.33

                  • PowerShares Dynamic Biotech&Genome Port

                  •  

                    311,441

                  • 0.00

                  • 0.91

                  • Vanguard Total Stock Mkt Idx

                  •  

                    242,521

                  • 45.35

                  • 0.70

                  • BlackRock Glb Global SmallCap Fund

                  •  

                    168,561

                  • -2.94

                  • 0.49

                  • Fidelity Advisor® Biotechnology Fund

                  •  

                    166,692

                  • 0.00

                  • 0.48

                  • iShares Russell 2000 (AU)

                  •  

                    154,157

                  • -1.03

                  • 0.45

                  • Institution Name

                  • Shares Held

                  • % Change

                  • % Outstanding

                  • Janus Capital Management LLC

                  •  

                    1,226,604

                  • +171.68%

                  • 3.56

                  • Consonance Capital Management LP

                  •  

                    1,188,316

                  • +48.10%

                  • 3.44

                  • Fidelity Management and Research Company

                  •  

                    1,036,170

                  • -7.46%

                  • 3.00

                  • BlackRock Fund Advisors

                  •  

                    650,326

                  • +7.57%

                  • 1.88

                  • Vanguard Group, Inc.

                  •  

                    493,389

                  • +2.91%

                  • 1.43

                  • BlackRock Advisors LLC

                  •  

                    399,663

                  • +177.37%

                  • 1.16

                  • Invesco PowerShares Capital Mgmt LLC

                  •  

                    356,203

                  • -6.75%

                  • 1.03

                  Company Profile

                  Sector

                  Healthcare

                  Industry

                  Biotechnology

                  Type

                  Speculative Growth

                  Style

                  Small Growth

                  Insys Therapeutics Inc was incorporated in Delaware in June 1990. The Company is a commercial-stage specialty pharmaceutical company. It develops and commercializes supportive care products. The Company has two marketed products Subs...moreys and Dronabinol SG Capsule. Subsys, a proprietary sublingual fentanyl spray for breakthrough cancer pain, or BTCP, in opioid-tolerant patients and Dronabinol SG Capsule, a generic equivalent to Marinol (dronabinol), an approved second-line treatment of chemotherapy-induced nausea and vomiting, or CINV, and anorexia associated with weight loss in patients with AIDS. It markets Subsys through an incentive-based sales model. Dronabinol SG Capsule is a dronabinol soft gelatin capsule that is a generic equivalent to Marinol, an approved second-line treatment for chemotherap...morey-induced nausea and vomiting (CINV) and anorexia associated with weight loss in patients with AIDS, offered in 2.5, 5.0 and 10.0 milligram dosages. The Company produces the Active Pharmaceutical Ingredient (API) for Dronabinol SG Capsule at its U.S.-based, state-of-the-art dronabinol manufacturing facility. The Company is subject to regulation by the FDA.lessless

                  Key People

                  Michael L. Babich

                  CEO/Director/President

                  Dr. John N. Kapoor,PhD

                  Chairman of the Board/Director

                  Darryl S. Baker

                  CFO/Chief Accounting Officer

                  Brian Tambi

                  Director

                  Steven J. Meyer

                  Director

                  • Insys Therapeutics Inc

                  • 444 South Ellis Street

                  • Chandler, AZ 85224

                  • USA.Map

                  • Phone: +1 602 910-2617

                  • Fax: +1 602 910-2627

                  • insysrx.com

                  Incorporated

                  1990

                  Employees

                  202

                  Send Feedback

                  We appreciate your input!

                  • I'm having trouble signing into my Microsoft account

                  • I’m having problems with the services stripe (Mail, Facebook, etc.)

                  • There is an issue with my weather information

                  • I see an error in the content

                  • Other

                  Please give an overall site rating: